In Phase A, participants will get different doses and schedules of oral ABBV-744 tablet to discover Secure dosing routine. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "incorporate-on" therapy. In https://albertd433qbl5.iyublog.com/profile